| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20015508 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20015091 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20021174 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20021369 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20070297 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20023782 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20023800 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20024110 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20015080 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
| TVIS20015084 | HPV | ENSG00000141736.14 | protein_coding | ERBB2 | Yes | No | 2064 | F5H1T4 J3QLU9 P04626 X5DNK3 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ERBB2 |
|---|---|
| DrugBank ID | DB11652 |
| Drug Name | Tucatinib |
| Target ID | BE0000511 |
| UniProt ID | P04626 |
| Regulation Type | inhibitor |
| PubMed IDs | 32241871; 29955792 |
| Citations | Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S: Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Mol Cancer Ther. 2020 Apr;19(4):976-987. doi: 10.1158/1535-7163.MCT-19-0873.@@Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, Chamberlain M, Gray T, Vo A, Hamilton E: Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2018 Sep 1;4(9):1214-1220. doi: 10.1001/jamaoncol.2018.1812. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3989868 |
